nach oben

The European Journal of Health Economics

Erschienen in:

05.07.2021 | Editorial

Public health policies for the common interest: rethinking EU states’ incentives strategies when a pandemic reshuffles all interests

verfasst von: Juan Del Llano, Jorge Mestre-Ferrandiz, Jaime Espin, Jordi Gol-Montserrat, Alicia del Llano, Carlos Bringas

Erschienen in: The European Journal of Health Economics | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Auszug

The paper “Should governments buy the drug patents?” published 13 years ago in this same journal [1] reflected on aspects that have become relevant again, both for good and bad reasons. The last 60 years have seen huge advances in many of the scientific, technological, and managerial factors that raises the efficiency of commercial medicines research and development (R&D). Yet the number of new medicines approved per US billion dollars spent on R&D has halved roughly every nine years since 1950, falling around 80-fold in inflation-adjusted terms [2]. …

Del Llano, J.: Discussion point: should governments buy drug patents? Eur. J. Health Econ. 8(2), 173–177 (2007)PubMedCrossRef

Espin, J., Schlander, M., Godman, B., Anderson, P., Mestre-Ferrandiz, J., Borget, I., et al.: Projecting pharmaceutical expenditure in EU5 to 2021: adjusting for the impact of discounts and rebates. Appl. Health Econ. Health Policy 16, 803–817 (2018). https://doi.org/10.1007/s40258-018-0419-1PubMedPubMedCentralCrossRef

Sarnak, D.O., Squires, D., Kuzmak, G., Bishop, S.: Paying for prescription drugs around the world: why is the US an outlier? Issue Brief (Commonw. Fund) 2017, 1–14 (2017)

Sarewitz, D.: Saving science. New Atlantis 49(Spring/Summer), 4–40 (2016)

European Comission: communication from the commission to the european parliament, the council, the european economic and social committee and the committee of the regions. https://ec.europa.eu/health/sites/health/files/human-use/docs/pharmastrategy_com2020-761_en.pdf

Spencer, D. Sanofi CEO Paul Hudson on GSK Vaccine Collaboration. https://pharmaboardroom.com/articles/sanofi-ceo-paul-hudson-on-gsk-vaccine-collaboration/

World Health Organization: WHO and Costa Rica preview technology pooling initiative to ensure access to COVID-19 health products for all. https://www.who.int/news/item/15-05-2020-who-and-costa-rica-preview-technology-pooling-initiative-to-ensure-access-to-covid-19-health-products-for-all

Financial Times: ‘People’s vaccine’ for coronavirus must be free, leaders urge. https://www.ft.com/content/af929941-7c02-415a-a692-bf8443ede58a

Institute for Clinical and Economic Review: Alternative Pricing Models for Remdesevir and Other Potential Treatments for COVID-19. http://icer.org/wp-content/uploads/2020/11/ICER-COVID_Updated_Report_11102020.pdf

10.

ICER: White Paper on Alternative Policies for Drug and Vaccine Pricing During a Pandemic, Announces Cross-Stakeholder Discussion Series. https://icer.org/news-insights/press-releases/updated_icer-covid_models_june_24/

11.

ICER: Alternative Pricing Models for Remdesivir as a Treatment for COVID-19. https://icer.org/news-insights/press-releases/alternative_pricing_models_for_remdesivir/

12.

Mestre-Ferrandiz, J., Zozaya, N., Alcalá, B., Hidalgo-Vega, A.: Multi-indication pricing: nice in theory but can it work in practice? Pharmacoeconomics 36, 1407 (2018). https://doi.org/10.1007/s40273-018-0716-4PubMedCrossRef

13.

Shaikh, M., Del Giudice, P., Kourouklis, D.: Revisiting the relationship between price regulation and pharmaceutical R&D investment. Appl. Health Econ. Health Policy (2020). https://doi.org/10.1007/s40258-020-00601-9PubMedCentralCrossRef

14.

Chalkidou, K., Claxton, K., Silverman, R., Yadav, P.: Value-based tiered pricing for universal health coverage: an idea worth revisiting [version 3; peer review: 3 approved]. Gates Open Res. 4:16 (2020). https://doi.org/10.12688/gatesopenres.13110.3

15.

Danzon, P.M., Towse, A.K., Mestre-Ferrandiz, J.: Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. 24(3), 294–301 (2013)PubMedCrossRef

16.

Csanádi, M., Kaló, Z., Prins, C., et al.: The implications of external price referencing on pharmaceutical list prices in Europe. Health Policy Technol. 7(3), 243–250 (2018). https://doi.org/10.1016/j.hlpt.2018.07.005CrossRef

17.

Panteli, D., Arickx, F., Cleemput, I., et al.: Pharmaceutical regulation in 15 European countries: review. Health Syst. Transit. 18(5), 1–118 (2016)PubMed

18.

Kanavos, P., Fontrier, A., Gill, J., et al.: Does external reference pricing deliver what it promises? Evidence on its impact at national level. Eur. J. Health Econ. 21, 129–151 (2020). https://doi.org/10.1007/s10198-019-01116-4PubMedCrossRef

19.

Shaw, B., Mestre-Ferrandiz, J.: Talkin’ about a resolution: issues in the push for greater transparency of medicine prices. Pharmacoeconomics 38, 125–134 (2020)PubMedCrossRef

20.

Sampat, B., Shadlen, C.: The COVID-19 innovation system. Health Aff. 40(3), 400–409 (2021)CrossRef

21.

Towse, A., Firth, I.: How should the world pay for a COVID-19 vaccine? Draft paper to accompany the 2020. OHE Annual Lecture. Office of Health Economics. Available: https://www.ohe.org/publications/%E2%80%9Chow-should-world-pay-covid-19-vaccine%E2%80%9D-draftlecture-paper (2020)

22.

Lobo, Cano, F.: La gran esperanza: las vacunas contra el coronavirus SARS-CoV-2, ¿mercado salvaje o mercado ordenado?, In: Perpiñán, J. M. A., Artero, C. C. (eds.) Economía de la salud (y más) de la COVID-19 (1ª edición). Asociación de Economía de la Salud (AES), Barcelona (2020). ISBN: 978-84-09-21542

23.

World Health Organization: Draft landscape and tracker of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed 20 June 2021

24.

Danzon, P., Pereira, N.S., Tejwani, S.S.: Vaccine supply: a cross-national perspective. Health Aff. 24(3), 706–717 (2005)CrossRef

25.

Stephenne, J., Danzon, P.: The New Global Economics of Vaccines: Will the Scientific Potential be Realised? Office of Health Economics, London (2008)

26.

Beall, R., Kuhn, R.: Trends in compulsory licensing of pharmaceuticals since the doha declaration: a database analysis. PLoS Med 9(1), e1001154 (2012). https://doi.org/10.1371/journal.pmed.1001154PubMedPubMedCentralCrossRef

27.

Abbas, M.Z.: Pros, and cons of compulsory licensing: an analysis of arguments. Int. J. Soc. Sci. Human. 3(3), 254–258 (2013). Available at SSRN: https://ssrn.com/abstract=2368116

28.

Gilead: Voluntary Licensing Agreements for Remdesivir. https://www.gilead.com/purpose/advancing-global-health/covid-19/voluntary-licensing-agreements-for-remdesivir. Accessed 11 February 2021

29.

Stigliz, J.: Prizes, not patent, post-autistic. Econ Rev 42, 48–49 (2007)

30.

Silverman, R., Krubiner, C., Chalkidou, K., Towse, A.: Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine. Center for Global Development. Available on https://www.cgdev.org/publication/financing-and-scaling-innovation-covid-fight-closer-look-demand-side-incentives-vaccine (2020)

31.

Advance Market Commitment for pneumococcal vaccines. Annual Report 1 January–31 December 2020. Prepared by the AMC Secretariat of GAVI, the Vaccine Alliance. Available https://www.gavi.org/sites/default/files/document/2021/2020-PCV-AMC-Annual-Report.pdf. Accessed 20 June 2021

32.

European Commission. Emergency Support Instrument. Available Emergency Support Instrument | European Commission (europa.eu). Accessed 21 June 2021 (2020)

33.

WHO, COVID-19 Technology Access Pool (C-TAP). Information available here: https://www.who.int/initiatives/covid-19-technology-access-pool. Last accessed 20 June 2021

34.

Alvarado Quesada, C., Adhanom Ghebreyesus, T.: The President of the Republic of Costa Rica and the Director-General of the World Health Organization call once again on all WHO Member States to actively support the COVID-19 Technology Access Pool (C-TAP). Accessed 20 June 2021 (2021)

35.

Mazzucato, M., Lishi Li, H., Darzi, A.: Is it time to nationalise the pharmaceutical industry? BMJ 368 (2020). https://doi.org/10.1136/bmj.m769. Published 04 March 2020

36.

Thorsteinsdóttir, H., Daar, A.S., Smith, R.D., Singer, P.A.: Genomics–a global public good? Lancet 361(9361), 891–892 (2003). https://doi.org/10.1016/S0140-6736(03)12786-9PubMedCrossRef

Titel: Public health policies for the common interest: rethinking EU states’ incentives strategies when a pandemic reshuffles all interests
verfasst von: Juan Del Llano
Jorge Mestre-Ferrandiz
Jaime Espin
Jordi Gol-Montserrat
Alicia del Llano
Carlos Bringas
Publikationsdatum: 05.07.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 3/2022
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-021-01341-w

Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK

Open Access
Original Paper

Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain

Open Access
Original Paper

The employment situation of people living with HIV: a closer look at the effects of the 2008 economic crisis

Original Paper

Does the amount of formal care affect informal care? Evidence among over-60s in France

Open Access
Original Paper

Income and conversion handicaps: estimating the impact of child chronic illness/disability on family income and the extra cost of child chronic illness/child disability in Ireland using a standard of living approach

Open Access
Original Paper

Valuing informal carers’ quality of life using best-worst scaling—Finnish preference weights for the Adult Social Care Outcomes Toolkit for carers (ASCOT-Carer)

Open Access
Original Paper

Springer Medizin

Public health policies for the common interest: rethinking EU states’ incentives strategies when a pandemic reshuffles all interests

Auszug

Weitere Artikel der Ausgabe 3/2022

Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK

Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain

The employment situation of people living with HIV: a closer look at the effects of the 2008 economic crisis

Does the amount of formal care affect informal care? Evidence among over-60s in France

Income and conversion handicaps: estimating the impact of child chronic illness/disability on family income and the extra cost of child chronic illness/child disability in Ireland using a standard of living approach

Valuing informal carers’ quality of life using best-worst scaling—Finnish preference weights for the Adult Social Care Outcomes Toolkit for carers (ASCOT-Carer)

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK

Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain

The employment situation of people living with HIV: a closer look at the effects of the 2008 economic crisis

Does the amount of formal care affect informal care? Evidence among over-60s in France

Income and conversion handicaps: estimating the impact of child chronic illness/disability on family income and the extra cost of child chronic illness/child disability in Ireland using a standard of living approach

Valuing informal carers’ quality of life using best-worst scaling—Finnish preference weights for the Adult ﻿Social Care Outcomes Toolkit for carers (ASCOT-Carer)

Valuing informal carers’ quality of life using best-worst scaling—Finnish preference weights for the Adult Social Care Outcomes Toolkit for carers (ASCOT-Carer)